Table 4.
Seroprevalence studies on antibodies targeting the Oropouche Virus from samples collected from the general population.
| Total Sample (N) | OROV-Positive Cases (n/N, %) | Risk Ratio (95%CI) | |
|---|---|---|---|
| Overall | 5247 | 1113, 21.21% | - |
| Timeframe | |||
| Before 1990 | 0 | - | - |
| 1991–2010 | 4085 | 1101, 26.95% | REFERENCE |
| After 2010 | 1162 | 12, 1.03% | 0.038 (0.022; 0.067) |
| Country | |||
| Brazil | 2625 | 646, 24.61% | REFERENCE |
| Colombia | 455 | 10, 2.20% | 0.089 (0.048; 0.165) |
| Peru | 2168 | 457, 21.08% | 0.857 (0.771; 0.952) |
| Antibody | |||
| IgG | 3896 | 1092, 28.03% | 18.655 (9.735; 35.746) |
| IgG/IgM | 753 | 12, 1.59% | 1.061 (0.450; 2.500) |
| IgM | 599 | 9, 1.50% | REFERENCE |
| Diagnostic procedure | |||
| ELISA | 4085 | 1101, 26.95% | REFERENCE |
| HAT | 298 | 2, 0.67% | 0.025 (0.006; 0.099) |
| PRT | 455 | 10, 2.20% | 0.082 (0.044; 0.151) |
| ICT | 410 | 0, - | 0.005 (0.001; 0.072) |
Note: OROV = Oropouche Virus; 95%CI = 95% confidence interval; ELISA = enzyme-linked immune assay; HAT = hemagglutination test; PRT = plaque reduction neutralization test; ICT = immunochromatographic test.